International AIDS Conference

Small study shows HIV patients not at a greater risk for worse outcomes.

The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.

With fostemsavir now available for patients with few options, an expert discusses what challenges MDR-HIV patients face in their care.

With insufficient HIV diagnosis testing in that country, this novel testing could help it reach part of its UNAIDS 90-90-90 targets.

A 34-year-old Brazilian man's HIV was undetectable 57 weeks after ending a heightened regimen of ART.

A look at the BRIGHTE study data which evidenced the recently FDA-approved add-on agent.

In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.

Despite being recommended at least once among all persons aged 13-64 years old by the CDC, notably few respondents have ever been tested for HIV.

Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.

Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.

A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.

Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.

A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.

CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.

Investigators report results of the first randomized clinical trial to test a novel strategy to wake up and kill dormant HIV hiding in reservoir cells.

Dolutegravir and lamivudine combination regimen met primary endpoint in 2 phase 3 studies of treatment-naïve patients with HIV.

Mosaic-based vaccine regimen maintained humoral and cellular HIV immune responses according to long-term data from APPROACH.

New guidelines on the prevention and treatment of HIV in adults from the IAS-USA Panel highlight advances made since the 2016 guidelines, as well as the need for new strategies.

PARTNER 2 study reports zero HIV transmissions over 8 years in gay couples who did not use condoms and had achieved an undetectable viral load on HIV treatment.